PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Webinar on Eryaspase in Pancreatic Cancer (September 1, 2021)
Presentation on the lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, featured by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell
View HTML
Toggle Summary ERYTECH to Participate in the Citi 16th Annual BioPharma Conference
ERYTECH to Participate in the Citi 16 th Annual BioPharma Conference Cambridge, MA (U.S.) and Lyon (France), August 30 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer Webinar on Wednesday, September 1 st @ 10am ET /4pm CET Cambridge, MA (U.S.) and Lyon (France), August 24 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company, leader in red
View HTML
Toggle Summary ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL
ERYTECH Granted U.S. FDA Fast Track Designation  for E ryaspase in Hypersensitive ALL Fast Track d esignation for eryaspase underscores the need for new treatment options for patients who developed hypersensitivity reactions to pegylated asparaginase Cambridge, MA (U.S.) and Lyon (France), July 29
View HTML
Toggle Summary ERYTECH to Participate in the BTIG Virtual Biotechnology Conference
ERYTECH to Participate in the BTIG Virtual Biotechnology Conference Cambridge, MA (U.S.) and Lyon (France) , Ju ly 2 7 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients
ERYTECH Confirms Plans To Submit BLA for E ryaspase in H ypersensitive ALL Patients M eeting with the U.S. FDA clarified steps and requirements for the submission of a Biologics License Application (BLA) for eryaspase for the treatment of ALL patients who developed hypersensitivity reactions to
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021
                 Monthly information related to total number of voting rights and shares composing the share capital – June 3 0 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN
View HTML
Toggle Summary Report - Erytech’s Combined Shareholders’ Meeting on June 25, 2021
        REPO R T - ERYTECH’S COMBINED SHAREHOLDERS’ MEE TING ON JUNE 25, 2021 SS RELEASE          Lyon (France), June 2 5 , 2021 – ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 202 1 Annual General Meeting was held in Lyon on Friday, June 25 , 2021 .
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021
                Monthly information related to total number of voting rights and shares composing the share capital – May 3 1 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN
View HTML
Toggle Summary ERYTECH to Participate in Upcoming Virtual Investor Conferences in June
ERYTECH to Participate in Upcoming Virtual Investor Conferences in June Lyon (France) and Cambridge, MA (U.S.), May 2 6 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Top